Incannex Healthcare (IXHL) Non-Current Assets (2022 - 2026)
Incannex Healthcare (IXHL) posted quarterly Non-Current Assets of $188000.0 for Q1 2026, down 66.9% year-on-year from $568000.0 in Q1 2025, and down 42.68% on a QoQ basis from $328000.0 in Q4 2025.
Incannex Healthcare (IXHL) Non-Current Assets (2022 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Non-Current Assets for 5 consecutive years, with $188000.0 the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets fell 66.9% year-over-year to $188000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 50.04% YoY) and the FY2025 annual result came in at $485000.0, down 42.6% from the prior year.
- Non-Current Assets retreated to $188000.0 in Q1 2026 per IXHL's latest filing, from $328000.0 in the prior quarter.
- Over the last five years, Non-Current Assets for IXHL reached as high as $53.1 million in Q4 2022 and fell as low as $188000.0 in Q1 2026.
- A 5-year average of $5.0 million and a median of $694000.0 in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 98.07% — and 2024, when it rose 7.51%.
- Year by year, Non-Current Assets stood at $53.1 million in 2022, then plunged by 98.07% to $1.0 million in 2023, then sank by 41.38% to $602000.0 in 2024, then slumped by 45.51% to $328000.0 in 2025, then sank by 42.68% to $188000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $188000.0, $328000.0, and $425000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 328,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | 485,000.00 |
| Mar 31, 2025 | 568,000.00 |
| Dec 31, 2024 | 602,000.00 |
| Sep 30, 2024 | 839,000.00 |
| Jun 30, 2024 | 845,000.00 |
| Mar 31, 2024 | 931,000.00 |
| Dec 31, 2023 | 1.03 Mn |
| Jun 30, 2023 | 786,000.00 |
| Dec 31, 2022 | 53.09 Mn |